Search
Now showing items 1-10 of 12
Prostate specific membrane antigen and DNA damage repair in advanced prostate cancer
(Institute of Cancer Research (University Of London), 2022-03-31)
Identification and implementation of novel therapeutic strategies for advanced prostate cancer (PCa) remains an urgent, unmet clinical need. Prostate Specific Membrane Antigen (PSMA), a PCa biomarker, is currently being ...
Combining large scale in silico analysis with fragment screening to identify novel, ligandable secondary sites in cancer-associated proteins
(Institute of Cancer Research (University Of London), 2020-01-31)
Proteins often have multiple binding sites involved in interactions with other molecules. The majority of currently approved drugs bind a protein's primary site, the major functional site in the protein. Targeting the ...
The molecular pathology of infant gliomas
(Institute of Cancer Research (University Of London), 2021-04-30)
Infant high grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumours. I have collected 241 cases ...
Applications of liquid biopsies in metastatic castration resistant prostate cancer
(Institute of Cancer Research (University Of London), 2020-02-29)
Despite many recent advances, treating advanced prostate cancer (PC) remains clinically challenging. The need for vaildated circulating biomarkers is well recognised in almost all cancers, including in PC. Whilst circulating ...
Exploiting the CRL4-CRBM E3 ubiquitin ligase complex for the development of iTAG: a versatile targeted protein degradation system to enable functional evaluation and target validation
(Institute of Cancer Research (University Of London), 2022-02-28)
Modulating target protein expression to probe for its relevance and function in a disease is critical in the drug discovery process of target validation. Current genetic methods and chemico-biology tools are widely employed ...
PET imaging to monitor NET-1 and GD2 expression in neuroblastoma
(Institute of Cancer Research (University Of London), 2021-01-31)
Within neuroblastoma (NB), approximately 50% of patients are considered high-risk, presenting widespread distant metastasis and, frequently, MYCN amplification. NB is further characterised by the selective presence of the ...
Fragment-based discovery of HSP70 inhibitors
(Institute of Cancer Research (University Of London), 2021-01-31)
Heat Shock Protein 70s (HSP70s) are key molecular chaperones that are overexpressed in many cancers and are often associated with metastasis and poor prognosis. Dual silencing of two isoforms, HSP72 and HSC70, using siRNA ...
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)
Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ...
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
Investigating acute cellular responses to elevated APOBEC3B expression
(Institute of Cancer Research (University Of London), 2021-09-30)
The cytosine deaminase APOBEC3B (A3B) functions as part of innate immunity by mutating viral DNA and preventing replication. Large-scale genome sequencing studies and examination of expression levels have identified mutations ...